146679-66-5

Basic information

• Product Name: 3-Bromopyridine-4-methanol
• Synonyms: 3-Bromopyridine-4-methanol;3-Bromo-4-pyridinemethanol;3-Bromo-4-(hydroxymethyl)pyridine;(3-Bromo-4-pyridyl)methanol;4-PyridineMethanol, 3-broMo-;(3-Bromopyridin-4-yl)
• CAS NO: 146679-66-5
• Molecular Formula: C₆H₆BrNO
• Molecular Weight: 188.023
• Mol File: 146679-66-5.mol

Chemical Properties

• Boiling Point: 287.079oC at 760 mmHg
• Flash Point: 127.421oC
• Appearance: /
• Density: 1.669g/cm3
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.599
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 12.72±0.10(Predicted)
• CAS DataBase Reference: 3-Bromopyridine-4-methanol(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Bromopyridine-4-methanol(146679-66-5)
• EPA Substance Registry System: 3-Bromopyridine-4-methanol(146679-66-5)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 146679-66-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical and Agrochemical Synthesis:
3-Bromopyridine-4-methanol is used as a key intermediate in the synthesis of various pharmaceuticals and agrochemicals. Its unique structure and reactivity allow for the development of new and effective compounds with potential therapeutic and pesticidal properties.
Used in Organic Synthesis:
3-Bromopyridine-4-methanol is used as a building block for the preparation of other organic compounds. Its versatile reactivity enables the synthesis of a wide range of organic molecules, contributing to the advancement of organic chemistry.
Used in Medicinal Chemistry and Drug Discovery:
3-Bromopyridine-4-methanol has potential applications in medicinal chemistry and drug discovery due to its pharmacological properties. Its unique structure allows for the exploration of its interactions with biological targets, potentially leading to the development of new drugs with improved efficacy and selectivity.

InChI:InChI=1/C6H6BrNO/c7-6-3-8-2-1-5(6)4-9/h1-3,9H,4H2

Upstream product

• 70201-43-3 3-bromo-pyridine-4-carbaldehyde 
• 13959-02-9 3-bromoisonicotinic acid 
• 79-22-1 methyl chloroformate 

Downstream Products

• 1017599-02-8 1'-benzyl-4-hydroxymethyl-2',3',5',6'-tetrahydro-1'H-[3,4']bipyridinyl-4'-ol 
• 1037830-81-1 3-bromo-4-(2-iodo-phenoxymethyl)-pyridine 
• 1357095-16-9 3-bromo-4-(methoxymethyl)pyridine 
• 1418117-80-2 3-bromo-4-(chloromethyl)pyridine hydrochloride 
• 157650-27-6 3-Cyano-4-hydroxymethylpyridin 
• 1620644-71-4 1-benzyl-4-((5,6-dimethoxy-1-oxo-2,3-dihydro-1H-inden-2 yl)methyl)pyridinium iodide 
• 1620644-73-6 1-benzyl-3-bromo-4-(5,6-dimethoxy-1-oxo-2,3-dihydro-1H-inden-2-yl)methylpyridinium iodide 
• 1620644-79-2 1-benzyl-3-acetyl-4-(5,6-dimethoxy-1-oxo-2,3-dihydro-1H-inden-2-yl) methyl pyridinium bromide 
• 1620644-81-6 1-benzyl-4-(5,6-dimethoxy-1-oxo-2,3-dihydro-1H-inden-2-yl) methyl-1,4-dihydropyridine-3-acetyl 

Relevant articles and documents

Discovery, Development, and SAR of Aminothiazoles as LIMK Inhibitors with Cellular Anti-Invasive Properties

As part of a program to develop a small molecule inhibitor of LIMK, a series of aminothiazole inhibitors were discovered by high throughput screening. Scaffold hopping and subsequent SAR directed development led to a series of low nanomolar inhibitors of LIMK1 and LIMK2 that also inhibited the direct biomarker p-cofilin in cells and inhibited the invasion of MDA MB-231-luc cells in a matrigel inverse invasion assay.

1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 BETA INHIBITORS

The present invention relates to the 1 H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta (GSK-3β) inhibitors and to their use in the treatment of GSK-3β-related disorders such as, for example, (i) insulin-resistance disorders; (ii) neurodegenerative diseases; (iii) mood disorders; (iv) schizophrenic disorders; (v) cancerous disorders; (vi) inflammation, (vii) osteoporosis, (viii) cardiac hypertrophy, (ix) epilepsies and (x) neuropathic pain.

SUBSTITUTED HETEROARYL ALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION

Provided are substituted heteroaryl aldehydes and derivatives thereof that act as allosteric modulators of hemoglobin, methods and intermediates for their preparation, pharmaceutical compositions comprising the modulators, and methods for their use in treating disorders mediate by hemoglobin and disorders that would benefit from increased tissue oxygenation.

5-ARYL-THIAZOL-2-YL-AMINE COMPOUNDS AND THEIR THERAPEUTIC USE

The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain 5-aryl-thiazol-2-yl-amine compounds of the following formula (I) (for convenience, collectively referred to herein as "5AT2A compounds"), which, inter alia, inhibit LIM kinase (LIMK) activity. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit LIMK activity, and in the treatment of diseases and conditions that are mediated by LIMK, that are ameliorated by the inhibition of LIMK activity, etc., including proliferative conditions such as cancer (e.g., breast cancer, prostate cancer, melanoma, glioma, etc.), as well as vasodilation (including, e.g., hypertension, angina, cerebral vasospasm, and ischemia following subarachnoid hemorrhage), neurodegenerative disorders, atherosclerosis, fibrosis, and inflammatory diseases (including, e.g., Crohn's disease and chronic obstructive pulmonary disease (COPD)), and glaucoma (also known as ocular hypertension). (Formula (I))

Oxidisable pyridine derivatives, their preparation and use as anti-Alzheimer agents

A compound of the formula (I) in which the dotted lines indicate the presence of at least one double bond; n = 0 to 4; R3 and R4 are H, or when n = 1, R3 and R4 can also form together a double bond between the carbon atoms, and m = 0, 1 or 2, Z is CH or N or Z is C and -CHR3- is =CH- linked by the double bond to the cyclopentanone; or -(-)m- is absent, and Z is NH, >N-alkyl, >N-phenyl, >N-benzyl or >N-heteroaryl; R8 is alkyl, aryl or heteroaryl which can be optionally substituted; EWG represents an electron withdrawing group selected from the group comprising COOR, COSR, CONRR', CN, COR, CF3, SOR, SO2R, SONRR', SO2NRR', NO2, halogen, heteroaryl; and the pharmaceutical salts or tautomers thereof. The compounds of formula (I) are potent in the treatment of neurodegenerative diseases such as Alzheimer's disease.

OXIDISABLE PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE AS ANTI-ALZHEIMER AGENTS

A compound of formula (I) in which the dotted lines indicate the presence of at least one double bond; n = 0 to 4; R3 and R4 are H, or when n = 1, R3 and R4 can also form together a double bond between the carbon atoms, and m = 0, 1 or 2, Z is CH or N or Z is C and - CHR3- is =CH- linked by the double bond to cyclopentanone; or - (-)m- is absent, and Z is NH, >N-alkyl, >N-phenyl, >N-benzyl or >N heteroaryl; R8 is alkyl, aryl or heteroaryl which can be optionally substituted; EWG represents an electron withdrawing group selected from the group comprising COOR, COSR, CONRR', CN, COR, CF3, SOR, SO2R, SONRR', SO2NRR', NO2, halogen, heteroaryl; and the pharmaceutical salts and stereisomers thereof. The compounds of formula (I) are potent in the treatment of neurodegenerative diseases such as Alzheimer's disease.

SUBSTITUTED HETEROARYL ALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION

Provided are substituted heteroaryl aldehydes and derivatives thereof that act as allosteric modulators of hemoglobin, methods and intermediates for their preparation, pharmaceutical compositions comprising the modulators, and methods for their use in treating disorders mediate by hemoglobin and disorders that would benefit from increased tissue oxygenation.

SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS

Disclosed are sulfonamide compounds of Formula (I): or stereoisomers, N-oxides, prodrugs, or pharmaceutically acceptable salts thereof, wherein ring A, R1, R2, R3, R4 and R5 are defined herein. Also disclosed are methods of using such compounds in the treatment of conditions related to CYP17 enzyme, such as cancer, and pharmaceutical compositions comprising such compounds.

ORGANIC COMPOUNDS

The present invention provides novel organic compounds of Formula (I): methods of use, and pharmaceutical compositions thereof.

An intra/intermolecular suzuki sequence to benzopyridyloxepines containing geometrically pure exocyclic tetrasubstituted alkenes

(Chemical Equation Presented) A route to enable the preparation of 5-benzylidenyl-benzopyridyloxepine analogues was developed to continue our research in the field of nuclear hormone receptor modulators. The key steps are1) a syn-stereoselective diboratio